Pfizer Investing In Gene Therapy Facility Seeking Treatments for Late-stage Duchenne Muscular Dystrophy

By John Heerdink LinkedIn

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products.

Reportedly, Pfizer is investing $500 million in Sanford, North Carolina to expand the manufacturing facility for gene therapy. The investment to add additional capacity to the facility for Pfizer’s experimental treatments for late-stage Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies among other gene therapies. Pfizer is seeking to be the first to bring a curative, late-stage treatment to DMD market.

To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

aug13(15)

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday. The investment will add additional capacity and capabilities to a facility that makes..

finance.yahoo.com

Read Full Article


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us